Yuebi Hu

1.9k total citations · 1 hit paper
10 papers, 1.0k citations indexed

About

Yuebi Hu is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Yuebi Hu has authored 10 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Yuebi Hu's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (3 papers). Yuebi Hu is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (3 papers). Yuebi Hu collaborates with scholars based in United States, China and Taiwan. Yuebi Hu's co-authors include Geoffrey R. Oxnard, Nora Feeney, Cloud P. Paweletz, Pasi A. Jänne, Lynette M. Sholl, Kathryn F. Mileham, Kenneth S. Thress, Philip Tracy, Hatim Husain and Suzanne E. Dahlberg and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Yuebi Hu

10 papers receiving 1.0k citations

Hit Papers

Assessment of Resistance ... 2018 2026 2020 2023 2018 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuebi Hu United States 7 739 533 521 369 158 10 1.0k
Nora Feeney United States 8 1.1k 1.5× 959 1.8× 772 1.5× 516 1.4× 245 1.6× 11 1.5k
Aleksandra Markovets United States 16 1.1k 1.5× 392 0.7× 834 1.6× 573 1.6× 127 0.8× 39 1.4k
Nicolas Pécuchet France 14 600 0.8× 557 1.0× 612 1.2× 366 1.0× 139 0.9× 31 1.1k
Neal Lindeman United States 7 372 0.5× 644 1.2× 339 0.7× 296 0.8× 216 1.4× 10 920
Zhanhong Xie China 18 519 0.7× 172 0.3× 761 1.5× 227 0.6× 108 0.7× 60 1.1k
Junpei Takashima Japan 4 718 1.0× 210 0.4× 604 1.2× 483 1.3× 104 0.7× 17 946
Kiyoko Kuwata Japan 14 599 0.8× 141 0.3× 555 1.1× 561 1.5× 140 0.9× 19 1.0k
Reiko Kaji Japan 20 1.0k 1.4× 249 0.5× 793 1.5× 236 0.6× 59 0.4× 44 1.2k
Valerio Gristina Italy 15 460 0.6× 341 0.6× 414 0.8× 298 0.8× 70 0.4× 54 809
Hielke J. Meulenbeld Netherlands 11 316 0.4× 176 0.3× 283 0.5× 149 0.4× 89 0.6× 17 577

Countries citing papers authored by Yuebi Hu

Since Specialization
Citations

This map shows the geographic impact of Yuebi Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuebi Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuebi Hu more than expected).

Fields of papers citing papers by Yuebi Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuebi Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuebi Hu. The network helps show where Yuebi Hu may publish in the future.

Co-authorship network of co-authors of Yuebi Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Yuebi Hu. A scholar is included among the top collaborators of Yuebi Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuebi Hu. Yuebi Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Liang, Na, Wen Ouyang, Zhidong Ma, et al.. (2020). Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Therapy. International Journal of Radiation Oncology*Biology*Physics. 108(3). e130–e130. 1 indexed citations
2.
Hu, Yuebi, Bryan C. Ulrich, Julianna Supplee, et al.. (2018). False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clinical Cancer Research. 24(18). 4437–4443. 290 indexed citations
3.
Meador, Catherine B., Yuebi Hu, James Chih‐Hsin Yang, et al.. (2018). Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. Journal of Clinical Oncology. 36(15_suppl). 9071–9071. 2 indexed citations
4.
Guibert, Nicolas, Yuebi Hu, Nora Feeney, et al.. (2018). Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Annals of Oncology. 29(4). 1049–1055. 89 indexed citations
5.
Oxnard, Geoffrey R., Yuebi Hu, Kathryn F. Mileham, et al.. (2018). Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncology. 4(11). 1527–1527. 513 indexed citations breakdown →
6.
Hu, Yuebi, Ryan S. Alden, Justin I. Odegaard, et al.. (2017). Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clinical Cancer Research. 23(23). 7351–7359. 63 indexed citations
7.
Hu, Yuebi, Angelo S. Mao, Rajiv M. Desai, et al.. (2017). Controlled self-assembly of alginate microgels by rapidly binding molecule pairs. Lab on a Chip. 17(14). 2481–2490. 34 indexed citations
8.
Oxnard, Geoffrey R., Yuebi Hu, Kathryn F. Mileham, et al.. (2017). OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms. Journal of Thoracic Oncology. 12(11). S1767–S1768. 13 indexed citations
9.
Guibert, Nicolas, Cloud P. Paweletz, Yuebi Hu, et al.. (2017). Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib.. Journal of Clinical Oncology. 35(15_suppl). 11529–11529. 8 indexed citations
10.
Oxnard, Geoffrey R., Yuebi Hu, Philip Tracy, et al.. (2017). Abstract 4112: Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC. Cancer Research. 77(13_Supplement). 4112–4112. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026